flutamide has been researched along with gemcitabine in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Maltais, R; Perreault, M; Poirier, D; Roy, J | 1 |
| Blagden, S; Blesing, C; Corrie, P; D'Ath, S; Mayer, A; Price, P; Shaw, J; Warner, N | 1 |
| Cafasso, D; Konduri, S; Schwarz, MA; Schwarz, RE | 1 |
1 review(s) available for flutamide and gemcitabine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for flutamide and gemcitabine
| Article | Year |
|---|---|
Phase II study to evaluate combining gemcitabine with flutamide in advanced pancreatic cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Flutamide; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | 2002 |
3 other study(ies) available for flutamide and gemcitabine
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Minor chemical modifications of the aminosteroid derivative RM-581 lead to major impact on its anticancer activity, metabolic stability and aqueous solubility.
Topics: Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Estranes; Humans; Liver; Molecular Structure; Solubility; Structure-Activity Relationship; Tumor Cells, Cultured; Water | 2020 |
Androgen receptor blockade in experimental combination therapy of pancreatic cancer.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Bevacizumab; Cell Division; Cell Line, Tumor; Deoxycytidine; Dihydrotestosterone; Drug Therapy, Combination; Flutamide; Gemcitabine; Humans; Immunohistochemistry; Mice; Mice, Nude; Pancreatic Neoplasms; Receptors, Androgen; Testosterone; Xenograft Model Antitumor Assays | 2007 |